AI Engines For more Details: Perplexity Kagi Labs You
Mitochondrial Toxicity: Atractyloside is a potent inhibitor of the mitochondrial ADP/ATP carrier protein (ANT), which plays a crucial role in cellular energy metabolism. By inhibiting ANT, atractyloside disrupts the transport of ATP (adenosine triphosphate), the primary energy currency of cells, leading to mitochondrial dysfunction and cellular energy depletion.
Organ Damage: Atractyloside toxicity primarily affects the liver and kidneys, although other organs may also be affected. In the liver, atractyloside-induced toxicity can cause hepatic necrosis (cell death) and liver failure. In the kidneys, it can lead to acute tubular necrosis and renal failure. The toxic effects on these organs can be severe and potentially life-threatening.
Metabolic Acidosis: Atractyloside poisoning can lead to metabolic acidosis, a condition characterized by an accumulation of acid in the body. This occurs as a result of impaired cellular respiration and the accumulation of metabolic byproducts such as lactic acid. Metabolic acidosis can disrupt normal physiological functions and lead to serious complications if left untreated.
Cardiovascular Effects: Atractyloside toxicity may also affect the cardiovascular system, leading to disturbances in heart rhythm (arrhythmias), hypotension (low blood pressure), and cardiovascular collapse. These effects can further contribute to the severity of atractyloside poisoning and complicate management.
Neurological Effects: In addition to its effects on vital organs, atractyloside poisoning can have neurological manifestations, including confusion, seizures, and coma. These neurological symptoms may result from the systemic effects of metabolic acidosis and cellular energy depletion.
Death: In severe cases of atractyloside poisoning, particularly when large amounts of the toxin are ingested, death can occur due to multi-organ failure, cardiovascular collapse, or respiratory arrest.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 1.7 | 0.6 | 1.83 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.4 | 0.8 | 0.75 |
| Allergies | 2.5 | 1.8 | 0.39 |
| Allergy to milk products | 1.4 | 1.2 | 0.17 |
| Alzheimer's disease | 2 | 3.5 | -0.75 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.6 | 1.33 |
| Ankylosing spondylitis | 2 | 0.9 | 1.22 |
| Anorexia Nervosa | 0.8 | 1.7 | -1.13 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 2.8 | 1.4 | 1 |
| Atherosclerosis | 1.2 | 0.7 | 0.71 |
| Atrial fibrillation | 1.8 | 1.2 | 0.5 |
| Autism | 3.8 | 3.8 | 0 |
| Autoimmune Disease | 0.9 | 1 | -0.11 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1.7 | 1.7 | 0 |
| Brain Trauma | 0.3 | 1.4 | -3.67 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.3 | 0.7 | -1.33 |
| Carcinoma | 1.8 | 0.9 | 1 |
| Celiac Disease | 0.9 | 1.7 | -0.89 |
| Cerebral Palsy | 1.1 | 1.1 | 0 |
| Chronic Fatigue Syndrome | 3.4 | 1.7 | 1 |
| Chronic Kidney Disease | 1.6 | 1.2 | 0.33 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.4 | -0.56 |
| Chronic Urticaria (Hives) | 1.4 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.9 | 0.8 | 0.13 |
| Cognitive Function | 0.9 | 1 | -0.11 |
| Colorectal Cancer | 2.9 | 1.6 | 0.81 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 1.2 | 1.5 | -0.25 |
| COVID-19 | 3.4 | 3.2 | 0.06 |
| Crohn's Disease | 3.6 | 2.2 | 0.64 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 1.1 | -0.22 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.2 | 1.1 | 0.09 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 4.4 | 3.7 | 0.19 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.1 | 0.5 | 1.2 |
| Endometriosis | 1.8 | 2 | -0.11 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.6 | 0.6 | 1.67 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 1.3 | 1.2 | 0.08 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 2.1 | 0.38 |
| gallstone disease (gsd) | 1.7 | 0.8 | 1.13 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | 0 |
| Generalized anxiety disorder | 1.8 | 1.3 | 0.38 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 0.8 | 0.5 | 0.6 |
| Graves' disease | 1.2 | 2 | -0.67 |
| Gulf War Syndrome | 0.5 | 0.3 | 0.67 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.9 | 1 | 0.9 |
| Heart Failure | 2.1 | 1.1 | 0.91 |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 1.1 | 0.6 | 0.83 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 1 | 0.6 | 0.67 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.9 | 2.3 | -0.21 |
| Hypothyroidism | 0.9 | -0.9 | |
| Hypoxia | 1.7 | 0.3 | 4.67 |
| IgA nephropathy (IgAN) | 0.9 | 1.9 | -1.11 |
| Inflammatory Bowel Disease | 3 | 3.8 | -0.27 |
| Insomnia | 0.9 | 1.7 | -0.89 |
| Intelligence | 1.3 | 1.3 | |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 3.1 | 2.8 | 0.11 |
| ischemic stroke | 1.7 | 1.4 | 0.21 |
| Liver Cirrhosis | 3.7 | 2.5 | 0.48 |
| Long COVID | 2.4 | 3.1 | -0.29 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 0.3 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.9 | -0.5 |
| ME/CFS with IBS | 0.3 | 0.8 | -1.67 |
| ME/CFS without IBS | 0.8 | 0.6 | 0.33 |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.2 | 3.2 | 0 |
| Mood Disorders | 4.2 | 3.8 | 0.11 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.3 | 2.2 | 0.05 |
| Multiple system atrophy (MSA) | 0.2 | 0.6 | -2 |
| myasthenia gravis | 0.6 | 0.7 | -0.17 |
| neuropathic pain | 0.3 | 1.7 | -4.67 |
| Neuropathy (all types) | 0.3 | 1.1 | -2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2.2 | 0.18 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.6 | 0.5 |
| Obesity | 3.8 | 3.1 | 0.23 |
| obsessive-compulsive disorder | 2.8 | 1 | 1.8 |
| Osteoarthritis | 1.3 | 0.9 | 0.44 |
| Osteoporosis | 2.5 | 0.3 | 7.33 |
| Parkinson's Disease | 3.7 | 3.1 | 0.19 |
| Polycystic ovary syndrome | 3.3 | 2.3 | 0.43 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | 0.4 | -0.33 |
| Primary sclerosing cholangitis | 0.9 | 0.8 | 0.13 |
| Psoriasis | 1.4 | 1.1 | 0.27 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.8 | 1.9 | 1 |
| Rosacea | 0.7 | 0.7 | 0 |
| Schizophrenia | 2.8 | 2.5 | 0.12 |
| scoliosis | 0.6 | 0.5 | 0.2 |
| Sjögren syndrome | 1 | 0.8 | 0.25 |
| Sleep Apnea | 1.2 | 1.7 | -0.42 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.2 | 6 |
| Stress / posttraumatic stress disorder | 1.6 | 1.8 | -0.13 |
| Systemic Lupus Erythematosus | 2 | 1.4 | 0.43 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 2.1 | 2.5 | -0.19 |
| Type 2 Diabetes | 3.1 | 3.1 | 0 |
| Ulcerative colitis | 2.3 | 2.5 | -0.09 |
| Unhealthy Ageing | 1.4 | 1.1 | 0.27 |
| Vitiligo | 1.2 | 0.7 | 0.71 |
